Adial Pharmaceuticals, Inc. ( ADIL) Stock. Should you Buy or Sell? $ 0.52
0.01 (1.89 %)
Adial Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | ADIL |
| Price | $0.52 |
| Beta | 0.400 |
| Volume Avg. | $775.4 thousand |
| Market Cap | $13.44 M |
| 52 Week Range | $0.43 - $5.08 |
Adial Pharmaceuticals, Inc. opened the day at $0.52 which is +'1.89 % on yesterday's close. Adial Pharmaceuticals, Inc. has a 52 week high of $5.08 and 52 week low of $0.43, which is a difference of $4.65. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $13.44 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Adial Pharmaceuticals, Inc. for $13.44 M, it would take 15 years to get your money back. Adial Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Adial Pharmaceuticals, Inc. Stock Forecast - Is Adial Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Strong Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -0.748 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Adial Pharmaceuticals, Inc.
| Price Book Value Ratio | 1.588 | Price To Book Ratio | 1.588 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -0.748 |
How liquid is Adial Pharmaceuticals, Inc.
| Current Ratio | 5.324 |
| Quick Ratio | 4.905 |
Debt
| Debt Ratio | 0.271 | Debt Equity Ratio | 0.372 |
| Long Term Debt To Capitalization | 0.022 | Total Debt To Capitalization | 0.028 |
Latest news about Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).
Onward Phase III Clinical Trial of Adial Pharmaceutical's AD04, a treatment for Alcohol Abuse Disorder, was completed in early 2022. A subset of study participants, the Heavy Drinker group, demonstrated clear benefit from AD04 with a 79% reduction in heavy drinking days, the primary end-points were not achieved in.
Shares of small-cap penny stock Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) shares are trading about 20.5% lower at $1.46 per share Wednesday morning. The company announced topline results for its Onward Phase 3 trial for AD04 in patients with Alcohol Use Disorder.
Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET
About Adial Pharmaceuticals, Inc.
Description :
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
